Biogen Inc. (0R1B.L) LSE

142.88

+4.54(+3.28%)

Updated at September 05 06:53PM

Currency In USD

Biogen Inc.

Address

225 Binney St

Cambridge, MA

United States of America

Phone

17814642000

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Employees

7605

First IPO Date

September 17, 1991

Key Executives

NameTitlePayYear Born
Mr. Christopher A. ViehbacherPresident, Chief Executive Officer & Director6.15M1961
Dr. Ginger Gregory Ph.D.Executive Vice President & Chief Human Resources Officer1.59M1968
Ms. Nicole MurphyExecutive Vice President and Head of Pharmaceutical Operations & Technology1.86M1973
Dr. Priya Singhal M.D., M.P.H.Executive Vice President & Head of Development1.95M1969
Ms. Susan H. Alexander Esq.Executive Vice President & Chief Legal Officer2.63M1957
Ms. Robin C. KramerExecutive Vice President & Chief Financial Officer01966
Mr. Sean GodboutChief Accounting Officer & Global Corporate Controller0N/A
Mr. Tim Power M.B.A., Ph.D.Head of Investor Relations0N/A
Ms. Natacha GassenbachChief Communication Officer & Head of Corporate Affairs0N/A
Mr. Adam Keeney Ph.D.Executive Vice President & Head of Corporate Development01977

Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.